The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
Subscribe To Our Newsletter & Stay Updated
